The new breakthrough in iron supplement by MegaPro Biomedical will benefit patients with kidney disease
There is a new breakthrough in the iron supplement for chronic kidney disease in Taiwan! The iron oxide nanoparticle injection (IOP Injection) developed by MegaPro Biomedical, a biotechnology company from ITRI has completed animal testing and safety evaluation. It is going to conduct its Phase I of the clinical trials, working towards its goal of launching the new drug into the market. It expects to launch its first drug in 2019, providing chronic kidney disease patients with fast and effective iron supplements.
Wang, Yue-Ru, the regulatory director for MegaPro Biomedical, stated that after its spin-off from ITRI in 2015, the team from MegaPro Biomedical completed the drug production, non-clinical effectiveness, and safety investigation as well as regulation establishment within a year. This year, MegaPro Biomedical was honored to be selected as the Index Case by Center for Drug Evaluation (CDE). In addition, the Industrial Development Bureau certified that the company fulfills the Biotech and New Pharmaceutical Development Act last month. In the same month, the company also began collaboration with Taipei Veterans General Hospital to conduct Phase I of IOP Injection clinical trial.
Jassy Wang, CEO of MegaPro Biomedical, stated that there is a huge demand for iron supplements amongst patients with kidney disease and the global intravenous iron supplement injection market is more than 1.6 billion USD annually. The IOP Injection developed by MegaPro Biomedical can provide sufficient iron supplement through a single injection, satisfying the fast-growing demand for iron supplements.
Jassy Wang also pointed out that in the future, MegaPro Biomedical will focus on the development of niche drugs with an emphasis on added value for human clinical trial and preclinical testing stage. The company also aims to provide top-notch biomedical technology for nanoparticles and nano-micelle, license the products to pharmaceutical companies, and become the source of Taiwanese nanomedicine in the future.